Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02AYL
|
|||
| Former ID |
DNC001088
|
|||
| Drug Name |
Pretomanid
|
|||
| Synonyms |
PA-824; 187235-37-6; Pretomanid; PA 824; PA824; UNII-2XOI31YC4N; (S)-PA 824; (S)-2-Nitro-6-((4-(trifluoromethoxy)benzyl)oxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; 2XOI31YC4N; CHEMBL227875; MMV688755; AK161427; (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine; (6S)-6,7-Dihydro-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-5H-imidazo[2,1-b][1,3]oxazine; Pretomanid [USAN:INN]; C14H12F3N3O5; PA-824(Pretomanid); AC1L9UFX; Pretomanid (USAN/INN); MLS006011141; SCHEMBL2983011
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Tuberculosis [ICD-11: 1B10-1B14] | Approved | [1] | |
| Mycobacterium infection [ICD-11: 1B10-1B21] | Phase 3 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12F3N3O5
|
|||
| Canonical SMILES |
C1C(COC2=NC(=CN21)[N+](=O)[O-])OCC3=CC=C(C=C3)OC(F)(F)F
|
|||
| InChI |
1S/C14H12F3N3O5/c15-14(16,17)25-10-3-1-9(2-4-10)7-23-11-5-19-6-12(20(21)22)18-13(19)24-8-11/h1-4,6,11H,5,7-8H2/t11-/m0/s1
|
|||
| InChIKey |
ZLHZLMOSPGACSZ-NSHDSACASA-N
|
|||
| CAS Number |
CAS 187235-37-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
602759, 11568219, 14754667, 56314347, 74512488, 92309397, 103516892, 109718929, 129919200, 134340334, 135143585, 136345878, 136348779, 136967299, 139347532, 144229765, 162223093, 162474735, 164046419, 164764023, 174006653, 174007389, 175426953, 179231147, 188889470, 196409666, 198982738, 210274726, 210280360, 223384013, 223554904, 223700553, 223705177, 223726250, 229040932, 241383546, 249855633, 250224263, 251971002, 252066562, 252434136, 252450233, 252553552
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mycobacterium Mycolic acid synthase (MycB cma) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | ClinicalTrials.gov (NCT02342886) Shortening Treatment by Advancing Novel Drugs. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.